Analyst Research

Report Title Price
Provider: Wright Reports
Provider: ValuEngine, Inc.
Provider: S&P Capital IQ Quantitative Report
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Senesco Technologies Inc Announces Highly Statistically Significant Tumor Growth Inhibition By Combination Of Lenalidomide And SNS01-T in Cancer Model

Monday, 13 Aug 2012 08:30am EDT 

Senesco Technologies Inc announced the results from the completed non-clinical study of SNS01-T in combination of lenalidomide in a model of multiple myeloma. Combining SNS01-T treatment with lenalidomide (the active ingredient in REVLIMID marketed by Celgene Corporation) inhibits tumor growth more effectively than either drug alone. All mice treated with the combination survived over 100 days to the end of the study. Tumors were eradicated after a single six week cycle of the combination in two thirds of the animals, and there was no regrowth after an additional eight weeks without further treatment. Mice implanted with human myeloma tumors derived from RPMI 8226 cells were randomized into 4 groups and treated with control nanoparticles, or, either SNS01-T (0.375 mg/kg; i.v., 2x per week), lenalidomide (50 mg/kg; i.p., 5x per week), or both. The mice received 2 cycles of treatment, 6 weeks and 5 weeks respectively, with an 11 day rest period between cycles. Mice, whose tumors were undetectable at the end of cycle 1, received no drug treatment in cycle 2 unless tumor reappeared. The mice were monitored for 2 weeks after the end of the second cycle of treatment. The total length of the study was 102 days. treatment. In conclusion, SNS01-T alone and in combination with 50 mg/kg of lenalidomide demonstrated significantly improved efficacy compared to lenalidomide alone. 

Company Quote

-0.07 -3.26%
11:37am EDT